Digital biomarkers

#Digital biomarkers #Monument Therapeutics #National Institutes of Health (NIH) #Neuroscience #Schizophrenia

Monument Therapeutics partners on novel treatment for schizophrenia

Monument Therapeutics and the Foundation for the National Institutes of Health (FNIH) will evaluate MT1988, in development for cognitive impairment associated with schizophrenia, in a proof-of-principle clinical trial.  Many individuals begin to show signs of schizophrenia months or even years before receiving a diagnosis, referred to as the ‘clinical high… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Alzheimer's #Automation #Biomarkers #Data automation #Data management #Digital biomarkers #Digitalisation #Drug development #Drug discovery #Genetics / genomics #Mass spectrometry / NMR #Neurodegenerative disorders #Neuroscience

New podcast: The far-reaching impact of drug discovery technology

This is the latest episode of the free DDW narrated podcast, titled “The far-reaching impact of drug discovery technology”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Accelerating time to market through digitalisation”, “… Read More

#News

#AI #Biomarkers #Clinical trials #Collaboration #Digital biomarkers #Nucleai #Precision medicine #Proscia

Proscia teams up with Nucleai to improve access to AI biomarkers

Software company Proscia has partnered with spatial AI biomarker company Nucleai in a collaboration aimed at improving precision medicine biomarkers for clinical trials.   The companies are integrating Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and will make them available as part of Proscia’s precision medicine AI portfolio.    The… Read More

#Business & Investment #News

Digital biomarkers
#AI / data analytics / healthtech / informatics #Biomarkers #Biosecurity #Clinical trials #Digital biomarkers

Beyond blood tests: The evolution of digital biomarkers in clinical research

Digital biomarkers promise to transform preventive medicine and clinical trials, but also raise issues of security, regulation and potential disparities in access. Deepika Khedekar, Clinical Trial Lead at IQVIA, provides an overview of the pros and cons, and suggests a possible solution. The human body, a complex tapestry of over… Read More

#Exclusive Content #Opinion

#Alzheimer's #Biomarkers #Digital biomarkers #Neurodegenerative disorders #Neuroscience

Why digital biomarkers will power tomorrow’s Alzheimer’s therapies

Listen to this article on the DDW Podcast: Rivka Kreitman, CIO of NeuraLight explores the landscape of therapies for Alzheimer’s and explains why digital biomarkers are key to combatting the disease. Neurodegenerative diseases – the collection of progressive conditions characterised by neuron cell damage and death and subsequent loss of motor… Read More

#Exclusive Content